Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Lisaiceland is here to bring you a fully blockchained, democratized, healthcare AI...
Lisaiceland is here to bring you a fully blockc...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Join the National Investor Network and get the latest information with your interests in mind.